Picton Mahoney Asset Management Lowers Holdings in Eli Lilly and Company $LLY

Picton Mahoney Asset Management lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 33.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,253 shares of the company’s stock after selling 14,470 shares during the period. Picton Mahoney Asset Management’s holdings in Eli Lilly and Company were worth $22,320,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in LLY. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph & Co. increased its holdings in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc boosted its stake in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.0%

Shares of Eli Lilly and Company stock opened at $1,007.37 on Wednesday. The company has a fifty day simple moving average of $1,050.71 and a 200-day simple moving average of $936.44. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The stock has a market cap of $950.31 billion, a price-to-earnings ratio of 43.89, a PEG ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the business earned $5.32 EPS. Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 30.15%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly says it is preparing to launch its oral obesity drug orforglipron in the U.S. as soon as Q2 pending FDA approval — a major revenue catalyst if approved and on schedule. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: Lilly won CHMP backing to expand Olumiant (baricitinib) use in adolescents with severe alopecia areata, which could broaden EU label and incremental sales. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Lilly advanced remternetug Alzheimer’s testing in China, extending its CNS pipeline geography and potential long?term growth optionality outside the U.S. Lilly Advances Remternetug Testing in China
• Positive Sentiment: Lilly advanced a Phase 1 oral diabetes candidate in China, reinforcing its diabetes/GLP pipeline breadth beyond injectable and obesity programs. Eli Lilly Advances New Oral Diabetes Drug In China
• Neutral Sentiment: Analyst coverage remains constructive overall (average “Moderate Buy”) and industry outlooks highlight Lilly as a core large?cap pharma to watch, supporting longer?term investor interest. Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Investor attention pieces and conference transcripts (TD Cowen) are circulating — helpful for transparency but not immediate stock drivers. TD Cowen Presentation Transcript
• Negative Sentiment: Competitive pressure: Novo Nordisk’s $506M expansion in Ireland signals stronger manufacturing scale for oral GLP medicines, a direct competitor to Lilly’s obesity/GLP lineup and a potential market?share headwind. Why Novo Nordisk’s Ireland expansion is key
• Negative Sentiment: Some editorial/analyst pieces argue investors should consider alternatives or note that Lilly’s valuation and recent momentum have cooled after a multi?year run, increasing sensitivity to any negative headlines. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. HSBC restated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. The Goldman Sachs Group set a $1,260.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Barclays began coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price objective on the stock. Bank of America decreased their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Finally, Cantor Fitzgerald increased their target price on Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,229.59.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.